pharma · Myotonic Dystrophy Type 1 · Myotonic Dystrophy Type 1 (DM1) · DYN
Dyne Therapeutics
Dyne Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2018
- Employees
- 276
- Programs
- 6
- Drugs
- 11
- Patents
- 82
Dyne Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Dyne Therapeutics.
Dyne Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
SODIUM CHLORIDE , DYNE-101
Dyne Therapeutics
Myotonic Dystrophy Type 1
1 trial -
zeleciment basivarsen (DYNE-101)
Dyne Therapeutics
Myotonic Dystrophy Type 1 (DM1)
1 trial -
DYNE-101
Dyne Therapeutics
Myotonic Dystrophy Type 1 (DM1)
1 trial -
DYNE-101 for Myotonic Dystrophy Type 1
Dyne Therapeutics
Myotonic Dystrophy Type 1
1 trial -
DYNE-251
Dyne Therapeutics
Duchenne Muscular Dystrophy (DMD)
1 trial -
DYNE251-DMD-201
Dyne Therapeutics
Duchenne muscular dystrophy
1 trial
Frequently asked questions
How many clinical projects does Dyne Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.